I was over my 2% cash target in my Taxable account at the end of last week, so I made another routine buy this week. Below are the details:
Account: Taxable
Date: 1/17/2023
Qty: 1 share
Price: $153.17
Avg Cost Basis: $134.20
Div Yield: 3.8%
Yield on Cost: 4.2%
Div/FCF: 45.36%
EPS: $7.51
P/E: 19.87
Scorecard: 5/6
- vs S&P - Current price is higher than average cost basis (+11.2%), but not outperforming market, +0.5
- FCF - Dividend Payout is less than 50% of FCF (45.4%), +1
- Conviction - High, has been one of my best performers and a large number of patents, +1
- Dividend Yield - 3.8% yield is higher than my portfolio average of 2.7%, but not in top 5% of >5% 0.5
- Weighting - Sector Weighting (8.2%) and Holding Weighting (3.6%) are both less than targets of 8.5% and 4.25%, +1
- P/E - 19.8 is less than 25, +1
PADI increased from $462.11 to $467.75 with this buy
Some other notes:
- $ABBV up to #5 weighted holding in my Taxable account
- Healthcare Sector and $ABBV weighting targets both met with buy
- This is the 5th time I have purchased $ABBV, and 4th time in the past 12 months
Since my weighting targets have been met with this buy,
$ABBV now drops in my Scorecard to a 4/6. We will have a new Scorecard leader this week. As of now,
$T,
$CARR and
$PEP are tied for the top spot. We will see how things shake out tomorrow and I'll make my buy decision for next week over the weekend.